Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies, Inc. (OTC: BSEM) generates news that reflects its role as a MedTech company focused on placental-derived allografts for advanced wound care and regenerative therapies. Coverage of BSEM often centers on clinical trial milestones, reimbursement developments, financial reporting, and operational updates related to its BioRetain®-processed product portfolio, which includes brands such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion™, and American Amnion AC™.
Investors and healthcare professionals following BSEM news can expect updates on randomized controlled trials and other clinical studies evaluating BioRetain-preserved placental allografts in chronic wound indications like diabetic foot ulcers and venous leg ulcers. The company has reported top-line clinical results from a multicenter randomized controlled trial in non-healing diabetic foot ulcers, as well as comparative studies versus standard of care and competitor products, and these types of announcements are key components of its news flow.
Another major theme in BioStem’s news is reimbursement and policy. The company regularly comments on Centers for Medicare & Medicaid Services (CMS) rules and Local Coverage Determinations affecting skin substitutes and cellular and tissue-based products. News items have addressed the placement of VENDAJE and VENDAJE AC in a “12-Month Status Quo” category under certain LCDs, the withdrawal of specific LCDs, and the inclusion of these products on Florida Medicaid’s list of covered skin substitutes, along with coverage in multiple state Medicaid programs.
Financial and corporate developments also feature prominently. BioStem has issued press releases on quarterly financial results, restated financial statements related to the treatment of bona fide services fees in a distribution agreement, and the appointment of a new independent registered public accounting firm. Operational news has included the purchase of land in the Research Park at Florida Atlantic University in Boca Raton, Florida, for a future headquarters, as well as partnerships to serve the U.S. Department of Veterans Affairs and community initiatives supporting veterans.
By monitoring this news page, readers can follow BioStem’s clinical evidence generation, reimbursement positioning, financial reporting, and strategic initiatives as they relate to its placental-derived advanced wound care products and BioRetain processing technology.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, will release its Q2 2025 financial results on August 14, 2025, followed by a conference call at 4:30 PM ET.
The conference call will feature CEO Jason Matuszewski and CFO Michael Fortunato discussing quarterly results and providing updates on the company's Form 10 filing and planned Nasdaq uplisting. The company's core business focuses on manufacturing allografts using their proprietary BioREtain® processing method, with products including AmnioWrap2™, VENDAJE®, and American Amnion™.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived wound care products, has responded to CMS's proposed changes for skin substitute reimbursement in CY 2026. The company supports the reform efforts aimed at addressing Medicare spending in this category.
CEO Jason Matuszewski emphasized their commitment to working with stakeholders during the 60-day comment period to optimize reimbursement methodology. The company is conducting randomized controlled trials (RCTs) for their BioREtain® technology across multiple indications, with initial results expected later this year.
Additionally, BioStem is progressing with its Form 10 filing and plans to provide updates on its Nasdaq uplisting during Q2 2025 earnings call.
BioStem Technologies (OTC: BSEM), a leading MedTech company specializing in placental-derived products for advanced wound care, announces that Chairman and CEO Jason Matuszewski will present at the Advanced Wound Care Summit's Investor Forum on July 15, 2025, at 2:00 PM ET in Boston.
The presentation, titled "Invest in the Future of Advanced Wound Care with BioStem Technologies," will showcase the company's core allograft business and growth opportunities. BioStem leverages its proprietary BioREtain® processing method and maintains AATB accreditation and FDA registration for its Pompano Beach facility. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion and American Amnion AC.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announces its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami. CEO Jason Matuszewski will engage in a fireside chat and one-on-one meetings.
BioStem Technologies leverages its proprietary BioREtain® processing method to develop and manufacture allografts. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products. Their facility in Pompano Beach, Florida, is FDA registered and AATB accredited, operating under cGTP and cGMP standards.